论文部分内容阅读
目的:研究卡培他滨不同给药方案用于治疗晚期消化道肿瘤的疗效。方法:将2012年于我院治疗晚期消化道肿瘤96例患者,随机平分成2组,观察组治疗以卡培他滨2000mg/m2,每天分2次口服,餐后30分钟服用,21天为1个周期,共治疗3个周期;对照组治疗以卡培他滨2500mg/m2,每天分2次口服,餐后30分钟服用,14天为1个周期,共治疗3个周期。对比2组疗效和不良反应发生率。结果:2组疗效差异无统计学意义(p>0.05),2组骨髓抑制、口腔炎发生率差异无统计学意义(p>0.05),观察组恶心呕吐、手足综合征、色素沉着发生率低于对照组(p<0.05)。结论:卡培他滨治疗晚期消化道肿瘤效果明显,选择合适的用药方案,不良反应较轻。
Objective: To study the curative effect of different capecitabine dosing regimens for the treatment of advanced gastrointestinal tumors. Methods: 96 patients with advanced gastrointestinal cancer treated in our hospital in 2012 were randomly divided into two groups. The observation group was treated with capecitabine 2000mg / m2 orally twice daily for 30 minutes and 21 days 1 cycle, a total of three cycles of treatment; control group to capecitabine 2500mg / m2, 2 times daily oral administration, 30 minutes after taking meal, 14 days for a cycle of 3 cycles. The efficacy and adverse reactions of two groups were compared. Results: There was no significant difference between the two groups (p> 0.05). There was no significant difference in the incidence of myelosuppression and stomatitis among the two groups (p> 0.05). The incidence of nausea and vomiting, hand-foot syndrome and pigmentation in the observation group was low In the control group (p <0.05). Conclusion: Capecitabine is effective in treatment of advanced gastrointestinal tumors. Choosing the appropriate drug regimen, the adverse reactions are mild.